A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AIR-DNase When Administered by Inhalation to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 May 2016
At a glance
- Drugs Alidornase alfa (Primary)
- Indications Cystic fibrosis; Emphysema
- Focus Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 09 May 2016 According to a Protalix BioTherapeutics media release, this trial is expected to initiate in mid-2016.
- 09 May 2016 According to a Protalix BioTherapeutics media release, status changed from recruiting to completed.
- 18 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2016.